Add this topic to your myFT Digest for news straight to your inbox
Patients in the US are waiting more than a week for results, by which time it’s probably too late
The question is how a return to work can be made safe without a vaccine?
Roche and Chugai provide lessons on how to keep a cross-border partnership intact
Consumers and doctors eager to understand who has immunity face uncertainty over testing and reliability
And trials of 20-minute swab test to determine coronavirus infection will start next week
Public Health England gives green light to second diagnostic kit to detect past infection and potential immunity
Approval for Roche project paves way for checks on who has had disease and who has potential immunity
Severin Schwan unapologetic for outspoken criticism of state responses to coronavirus
Lack of spending means Britain trails behind in coronavirus testing, says Swiss group’s head
The whipsawing after economies locked down begins again as hopes rise of cities reopening
Process allows medics to check who has already had the disease and how far immunity is developing
Study argues prices for potential treatments are far higher than the actual cost of production
Resources and trial data will be shared with governments and each other
Worldwide efforts intensify to find drug that counters deadly disease
Setback deals another blow to most common hypothesis about causes of the disease
Swiss drugmaker looks to new medicines to offset rising competition from copycat products
Wait period extended after watchdogs in US and UK request more information about deal
Deal may turn Swiss group from a laggard into a leader in gene therapy
Buyout is latest example of rush by big pharma to scoop up promising biotech firms
Pharmaceuticals chief will replace John Milligan who announced his departure in July
Sales growth and drug approvals accelerate in world’s second-largest market
International Edition